Rentschler, Pall Expand; Recipharm Evaluates Future of UK Solid-Dose Mfg Facility

By Patricia Van Arnum - DCAT Editorial Director

January 3, 2019

A roundup of news from suppliers, contract development and manufacturing organizations, and contract manufacturing organizations, featuring news from Rentschler Biopharma, Pall, Recipharm, 3P Biopharmaceuticals, Fujifilm Irvine Scientific, and Roquette.

Biologics Manufacturing

Rentschler Biopharma to Purchase US Manufacturing Site from Shire 

Rentschler Biopharma SE, a Laupheim, Germany-headquartered contract development and manufacturing organization (CDMO) for biopharmaceuticals, has signed an agreement to purchase a manufacturing facility from an affiliate of Shire in Milford near Boston, Massachusetts.

The development and manufacturing site will be leveraged as a CDMO by Rentschler Biopharma. Under the agreement, Rentschler Biopharma will continue to manufacture product for Shire at the site.

The closing of the transaction is subject to the prior satisfaction or waiver of certain closing conditions. Financial terms of the transaction were not disclosed.

Source: Rentschler Biopharma

Pall Opens Center of Excellence in Shanghai

Pall Corporation, a provider of filtration, separation, and purification products and services, has established a Biotech Integrated Solutions Center of Excellence (CoE) in Shanghai, China.

The CoE is a new facility for bioprocess engineering consultancy, technology demonstration, testing and training for China and broader Asia. Equipped with advanced bioprocessing equipment and automation platforms, the CoE has end-to-end technological services for biomanufacturing, including single-use cell-culture solutions, cell clarification using acoustic wave technology, chromatography using automated packing techniques, viral clearance, tangential flow filtration and mixer/container modules.

Source: Pall Corporation

3P Biopharmaceuticals Completes $5-Million Expansion

3P Biopharmaceuticals (3P), a Noáin, Spain-headquartered contract development and manufacturing organization for biologics, has completed a EUR 5 million ($5.7 million) project for the expansion and improvement of its facilities in Noáin that had been carried out over the past months.

Source: 3P Biopharmaceuticals

Fujifilm Irvine Scientific Launches New Company Name

Irvine Scientific Sales Company, a US subsidiary of Fujifilm Corporation and a provider of cell-culture media, has changed its name to Fujifilm Irvine Scientific, Inc. (FISI), effective January 1, 2019.

FISI provides a wide range of products, including cell-culture media for biopharmaceutical production, in vitro fertilization, and cell therapy. The company is based in Santa Ana, California.

Source: Fujifilm Irvine Scientific

Formulation Development/Drug Product Manufacturing

Recipharm To Potentially End Operations in UK Facility

Recipharm plans to initiate a process to explore the discontinuance of operations at its solid-dose manufacturing facility in Ashton-under-Lyne, UK.

The decision to initiate this process has been taken following a strategic review of the operation, which has not been profitable for several years, says Recipharm. The facility employs approximately 140 people, and if a final decision is taken to discontinue operations these people are likely to be affected, according to information from Recipharm.

Source: Recipharm

Roquette, Thermo Fisher Scientific in Excipient Distribution Pact

Roquette, a La Madeleine, France-based provider of excipients and food ingredients, and Thermo Fisher Scientific have formed a distribution rights agreement for Roquette’s portfolio of pharmaceutical ingredients in the US and Canada.

The collaboration combines the chemical storage and supply-chain services from Doe & Ingalls, a brand of Thermo Fisher Scientific, with the pharmaceutical ingredients. The full portfolio of Roquette pharmaceutical ingredients will be included in the distribution agreement, including the newly launched Kleptose BioPharma HPB/HP grades hydroxypropyl β-cyclodextrins, recently acquired microcrystalline cellulose products and other excipients.

Source: Roquette